Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Executive Summary
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
You may also be interested in...
Korea Eases Stock Rules To Help Bioventures Stay Listed, Focus On R&D
South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities.
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
OliX Eyes RNAi Leadership In Asia And Beyond
Emerging Company Profile: Alnylam's success with late-stage patisiran raised expectations for other RNAi firms, like South Korea's OliX Pharmaceuticals. OliX is developing locally administered treatments for dermal, ophthalmic and pulmonary indications in hopes of cementing its leadership in Asia and beyond.